Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
Cornell University · Neurological Surgery · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,070
total citations
- FWCI
- 57.68
- Percentile
- 100%
- References
- 34
Citations per year
Authors
11- MGMichael G. KaplittCorresponding
Cornell University, Neurological Surgery
- AFAndrew Feigin
Center for Neurosciences, New York University, Northwell Health, Feinstein Institute for Medical Research
- CTChengke Tang
Center for Neurosciences, Northwell Health, Feinstein Institute for Medical Research
- HLHelen L. Fitzsimons
Neurology, Inc
- PJPaul J. Mattis
Feinstein Institute for Medical Research, Northwell Health, Center for Neurosciences
Topics & keywords
Topics
Keywords
- Tolerability
- Subthalamic nucleus
- Medicine
- Adverse effect
- Parkinson's disease
- Deep brain stimulation
- Internal medicine
- Disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.